Viewing Study NCT07315750

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2026-03-26 @ 3:15 PM

Ignite Modification Date: 2026-03-30 @ 2:38 AM

Study NCT ID: NCT07315750

Status: RECRUITING

Last Update Posted: 2026-01-21

First Post: 2025-12-03

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Sponsor: RemeGen Co., Ltd.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module